Macular Edema and Macular Degeneration Market Size Outlook and Demand Growth Across 2026–2030
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Macular Edema and Macular Degeneration Market During 2026–2030?
The macular edema and macular degeneration market size has seen significant expansion in recent years. It is anticipated to increase from $10.33 billion in 2025 to $11.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The historical growth of this market can be ascribed to several factors, including the rising occurrence of diabetes and retinal disorders, an aging demographic with a greater risk of vision impairment, the effectiveness of anti-VEGF injections in clinical settings, increased public understanding of macular diseases, and the expansion of ophthalmology clinics.
The macular edema and macular degeneration market is anticipated to experience substantial growth in the upcoming years, with projections indicating an expansion to $14.33 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.8%. This projected increase during the forecast period is primarily fueled by a rising global diabetic population, intensified screening for retinal diseases, an increasing preference for minimally invasive eye treatments, wider access to advanced ophthalmic care, and greater healthcare spending dedicated to vision preservation. Significant trends expected in this period encompass the growing adoption of anti-VEGF based therapies, an escalating demand for early diagnosis and intervention, the increased application of combination drug and laser therapies, a heightened focus on managing diabetic eye complications, and the ongoing expansion of outpatient and clinic-based eye care services.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
What Underlying Factors Are Accelerating The Growth Of The Macular Edema and Macular Degeneration Market?
The increasing number of people with diabetes is anticipated to fuel the expansion of the macular edema and macular degeneration market in the future. Diabetes is a chronic health condition marked by elevated glucose (sugar) levels in the bloodstream. This condition can damage the blood vessels within the eye, potentially leading to the development of macular edema and macular degeneration. For instance, in June 2024, as per The National Health Service (NHS England), a publicly funded healthcare provider in the UK, the number of individuals identified with pre-diabetes by the NHS in England reached 3,615,330 in 2023, indicating an 18% increase from 3,065,825 recorded in 2022. Moreover, cases among those under 40 years old significantly rose by nearly 25%, climbing from 173,166 in 2022 to 216,440 in 2023. Consequently, the expanding diabetes population is a key factor driving the growth of the macular edema and macular degeneration market.
How Are The Various Segments Of The Macular Edema and Macular Degeneration Market Categorized?
The macular edema and macular degeneration market covered in this report is segmented –
1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation, Subthreshold Laser Therapy, MicroPulse Laser Therapy
Which Market Trends Are Creating New Opportunities In The Macular Edema and Macular Degeneration Market?
Leading firms in the macular edema and macular degeneration market are concentrating on creating novel solutions, such as continuous-delivery ocular implants, to lessen the burden of treatment, boost patient compliance, and ensure more stable, long-term therapeutic results. These ocular implants are compact, replenishable devices inserted into the eye, designed to gradually dispense medication over extended periods, thereby minimizing the necessity for frequent injections and offering consistent, prolonged therapy for retinal conditions. For instance, in February 2025, F. Hoffmann-La Roche Ltd, a Switzerland-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) authorization for Susvimo. Susvimo is a refillable ocular implant that administers the anti-VEGF medication ranibizumab for treating diabetic macular edema (DME). Susvimo functions as a long-lasting, surgically placed reservoir engineered to consistently release a tailored version of ranibizumab, thereby sustaining therapeutic drug concentrations for prolonged periods. In contrast to conventional anti-VEGF intravitreal injections, which frequently necessitate monthly or bi-monthly doses, Susvimo provides a refill-exchange period of approximately six months, significantly alleviating the patient’s treatment load. This sustained-delivery approach improves adherence, simplifies clinical procedures, and delivers lasting anatomical and visual advantages for individuals suffering from chronic retinal disease.
Which Major Firms Influence Developments In The Macular Edema and Macular Degeneration Market?
Major companies operating in the macular edema and macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., Ocugen Inc.
Read the full macular edema and macular degeneration market report here:
Which Region Is Projected To Dominate The Macular Edema and Macular Degeneration Market During The Forecast Period?
North America was the largest region in the macular edema and macular degeneration market in 2025. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Macular Edema and Macular Degeneration Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp
Browse Through More Reports Similar to the Global Macular Edema and Macular Degeneration Market 2026, By The Business Research Company
Macular Edema And Macular Degeneration Global Market Report
Age Related Macular Degeneration Global Market Report
Retinal Disorder Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
